FARMINGDALE, N.Y., March 5, 2013 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announces a new clinical paper accepted for publication by "The International Journal of Oral & Maxillofacial Surgery," a well-respected, peer-reviewed journal. Entitled "Ultrasonic Orthognathic Surgery; Enhancements to Established Osteotomies," authored by Gilles, Couvreur and Dammous, from the Department of Oral and Maxillofacial Surgery, Clinique de Esperance, Montegnee, Belgium, the clinical paper is circulated to leading oral, maxillofacial and reconstructive surgeons. Orthognathic surgery refers to the correction of abnormal conditions affecting the jaw or face; osteotomies refer to the bone dissection (cutting) necessary to reposition bone during these surgeries. Given the attributes of the Misonix BoneScalpel, as described below, the use of traditional power instruments, such as saws or burrs, was unnecessary for this study.
It was noted that the Misonix® BoneScalpel Ultrasonic Bone Cutter (osteotome) offers a safe and efficient method to create precise cuts during the transection of bone during reconstructive surgery of the jaw and face, generally required as a result of birth defects and other abnormalities. Primary advantages, as reported, include improved control, a largely bloodless operative field for improved visualization, precise osteotomies (cuts through bone), significant reductions in the occurrence of nerve impairment, and significant reductions in 'bad bone splits' that may require additional corrective surgery.
In the words of Dr. Roland Gilles, MD, DDS, one of the clinical investigators; "We adapted the ultrasonic blade of the BoneScalpel to serve as a universal instrument for orthognathic and maxillofacial surgery. We have since performed well over 100 procedures including orthognathic, reconstructive and oncologic surgeries. Using the BoneScalpel, we have much better control over the osteotomy and have observed significantly fewer bad splits and reductions in nerve impairment, swelling, hematoma, operative time and hospital stay."
The Misonix® BoneScalpel™, which was used to perform the study, is a novel ultrasonic osteotome (bone cutting device) used for safe, tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures. Most users report that the surgical field is relatively bloodless and clean. Loss of viable bone is minimal and controllable. In addition to maxillofacial and reconstructive surgery, the BoneScalpel has been used extensively for bone removal in the cervical, thoracic and lumbar spine, including spinal deformity surgery.
"We are proud to report such an impressive clinical experience with the Misonix BoneScalpel when used in advanced orthognathic surgery," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "In many procedures in spine surgery, as well as maxillofacial surgery, we are now seeing that surgeons are finding less bleeding, as was observed by Dr. Gilles, et al, which contributes to faster, safer procedures that require less time in the hospital. It is our privilege to work with world renowned surgeons and to provide state of the art ultrasonic surgical technology to prestigious institutions throughout the world."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.